Last reviewed · How we verify
polyICLC
At a glance
| Generic name | polyICLC |
|---|---|
| Also known as | Hiltinol |
| Sponsor | Craig L Slingluff, Jr |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma (EARLY_PHASE1)
- Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (PHASE1, PHASE2)
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (PHASE1)
- Dendritic Cell Vaccine for Patients With Brain Tumors (PHASE2)
- Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (PHASE1, PHASE2)
- Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (PHASE1, PHASE2)
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (PHASE1, PHASE2)
- Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- polyICLC CI brief — competitive landscape report
- polyICLC updates RSS · CI watch RSS
- Craig L Slingluff, Jr portfolio CI